Eidos Therapeutics, a BridgeBio Company
Clinical trials sponsored by Eidos Therapeutics, a BridgeBio Company, explained in plain language.
A subsidiary of BridgeBio Pharma, focused on developing therapies for transthyretin amyloidosis.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Heart drug acoramidis tested for Long-Term cardiac repair in rare amyloidosis
Disease control Recruiting nowThis study tests the drug acoramidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart, weakening it. Over 36 months, researchers measure whether acoramidis improves heart function and structure using cardiac …
Phase 4 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug aims to stop rare genetic disease before it strikes
Prevention Recruiting nowThis phase 3 trial tests whether acoramidis can prevent or delay transthyretin amyloidosis (ATTR) in 587 adults who carry a faulty gene but have no symptoms yet. ATTR causes sticky plaques to build up in the heart and nerves, leading to heart failure and nerve damage. Acoramidis …
Phase 3 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Prevention
Last updated Aug 06, 2026 00:00 UTC